Breyanzi European Union - English - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastic agents - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

JINYINGZI YIFANG Singapore - English - HSA (Health Sciences Authority)

jinyingzi yifang

top 1 wellness (s) international group pte. ltd. - granules (internal use)

JINYINHUA YIFANG Singapore - English - HSA (Health Sciences Authority)

jinyinhua yifang

top 1 wellness (s) international group pte. ltd. - granules (internal use)

MIJINYINGZI YIFANG Singapore - English - HSA (Health Sciences Authority)

mijinyingzi yifang

top 1 wellness (s) international group pte. ltd. - granules (internal use)